The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2
Abstract
Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vasodilator and antitrophic heptapeptide, angiotensin-(1–7) [Ang-(1–7)]. As the only known human homolog of ACE, the demonstration that ACE2 is insensitive to blockade by ACE inhibitors prompted us to define the effect of ACE inhibition on the ACE2 gene. Methods and Results— Blood pressure, cardiac rate, and plasma and cardiac tissue levels of Ang II and Ang-(1–7), together with cardiac ACE2, neprilysin, Ang II type 1 receptor (AT 1 ), and mas receptor mRNAs, were measured in Lewis rats 12 days after continuous administration of vehicle, lisinopril, losartan, or both drugs combined in their drinking water. Equivalent decreases in blood pressure were obtained in rats given lisinopril or losartan alone or in combination. ACE inhibitor therapy caused a 1.8-fold increase in plasma Ang-(1–7), decreased plasma Ang II, and increased cardiac ACE2 mRNA but not cardiac ACE2 activity. Losartan increased plasma levels of both Ang II and Ang-(1–7), as well as cardiac ACE2 mRNA and cardiac ACE2 activity. Combination therapy duplicated the effects found in rats medicated with lisinopril, except that cardiac ACE2 mRNA fell to values found in vehicle-treated rats. Losartan treatment but not lisinopril increased cardiac tissue levels of Ang II and Ang-(1–7), whereas none of the treatments had an effect on cardiac neprilysin mRNA. Conclusions— Selective blockade of either Ang II synthesis or activity induced increases in cardiac ACE2 gene expression and cardiac ACE2 activity, whereas the combination of losartan and lisinopril was associated with elevated cardiac ACE2 activity but not cardiac ACE2 mRNA. Although the predominant effect of ACE inhibition may result from the combined effect of reduced Ang II formation and Ang-(1–7) metabolism, the antihypertensive action of AT 1 antagonists may in part be due to increased Ang II metabolism by ACE2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485
A Human Homolog of Angiotensin-converting Enzyme
Tipnis, S. R., Hooper, N. M., Hyde, R., Karran, E., Christie, G., & Turner, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002615200 · Cited by 2,009
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733
Self-citationHydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200581200 · Cited by 1,407
Towler, P., Staker, B., Prasad, S. G., Menon, S., Tang, J., Parsons, T., Ryan, D., Fisher, M., Williams, D., Dales, N. A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311191200 · Cited by 696
RICE, G. I., THOMAS, D. A., GRANT, P. J., TURNER, A. J., & HOOPER, N. M. (2004) · Biochemical Journal · doi:10.1042/bj20040634 · Cited by 619
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Self-citationCardiac Actions of Angiotensin II: Role of an Intracardiac Renin-Angiotensin System
Baker, K. M., Booz, G. W., & Dostal, D. E. (1992) · Annual Review of Physiology · doi:10.1146/annurev.ph.54.030192.001303 · Cited by 517
Counterregulatory Actions of Angiotensin-(1-7)
Ferrario, C. M., Chappell, M. C., Tallant, E. A., Brosnihan, K. B., & Diz, D. I. (1997) · Hypertension · doi:10.1161/01.hyp.30.3.535 · Cited by 509
Self-citation
Cited by
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Endothelial cell infection and endotheliitis in COVID-19
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30937-5 · Cited by 6,358
COVID-19 and its implications for thrombosis and anticoagulation
Connors, J. M., & Levy, J. H. (2020) · Blood · doi:10.1182/blood.2020006000 · Cited by 2,369
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
COVID-19 and cardiovascular disease
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046941 · Cited by 1,738
Grasselli, G., Greco, M., Zanella, A., Albano, G., Antonelli, M., Bellani, G., Bonanomi, E., Cabrini, L., Carlesso, E., Castelli, G., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.3539 · Cited by 1,612
Guzik, T. J., Mohiddin, S. A., Dimarco, A., Patel, V., Savvatis, K., Marelli-Berg, F. M., Madhur, M. S., Tomaszewski, M., Maffia, P., D’Acquisto, F., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa106 · Cited by 1,440
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D., & Patel, A. N. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007621 · Cited by 1,428
RetractedCOVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
The pivotal link between ACE2 deficiency and SARS-CoV-2 infection
Verdecchia, P., Cavallini, C., Spanevello, A., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.037 · Cited by 1,237
“The possibility that ACE inhibitors and angiotensin II receptor blockers (ARBs) may be discontinued even temporarily, because these drugs appear to increase the expression of ACE2 receptors, the site of viral entry into the human organism, [72] [73] [74] [75] is actively debated.”
SARS-CoV-2 and viral sepsis: observations and hypotheses
Li, H., Liu, L., Zhang, D., Xu, J., Dai, H., Tang, N., Su, X., & Cao, B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30920-x · Cited by 1,178
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.317134 · Cited by 1,133
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19
Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006923 · Cited by 1,073
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008975 · Cited by 1,063
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Cardiovascular disease and COVID-19
Bansal, M. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.03.013 · Cited by 999
COVID-19 pandemic, coronaviruses, and diabetes mellitus
Muniyappa, R., & Gubbi, S. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00124.2020 · Cited by 869
Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833
COVID-19 with Different Severities: A Multicenter Study of Clinical Features
Feng, Y., Ling, Y., Bai, T., Xie, Y., Huang, J., Li, J., Xiong, W., Yang, D., Chen, R., Lu, F., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0445oc · Cited by 838
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
McGonagle, D., O'Donnell, J. S., Sharif, K., Emery, P., & Bridgewood, C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30121-1 · Cited by 824
COVID-19, ACE2, and the cardiovascular consequences
South, A. M., Diz, D. I., & Chappell, M. C. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00217.2020 · Cited by 762
Self-citationVascular Smooth Muscle Cells and Arterial Stiffening: Relevance in Development, Aging, and Disease
Lacolley, P., Regnault, V., Segers, P., & Laurent, S. (2017) · Physiological Reviews · doi:10.1152/physrev.00003.2017 · Cited by 734
Renin‐angiotensin system revisited
Fyhrquist, F., & Saijonmaa, O. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01981.x · Cited by 642
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
D’Amico, F., Baumgart, D. C., Danese, S., & Peyrin-Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.001 · Cited by 599
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Cheng, H., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25785 · Cited by 548
Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1624 · Cited by 541
Hanley, B., Naresh, K. N., Roufosse, C., Nicholson, A. G., Weir, J., Cooke, G. S., Thursz, M., Manousou, P., Corbett, R., Goldin, R., et al. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30115-4 · Cited by 535
Ssentongo, P., Ssentongo, A. E., Heilbrunn, E. S., Ba, D. M., & Chinchilli, V. M. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238215 · Cited by 532
Acute kidney injury in critically ill patients with COVID-19
Gabarre, P., Dumas, G., Dupont, T., Darmon, M., Azoulay, E., & Zafrani, L. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06153-9 · Cited by 529
Obesity and diabetes as high‐risk factors for severe coronavirus disease 2019 (Covid‐19)
Zhou, Y., Chi, J., Lv, W., & Wang, Y. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3377 · Cited by 490
Kuba, K., Imai, Y., Ohto-Nakanishi, T., & Penninger, J. M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.06.003 · Cited by 480
Guo, J., Huang, Z., Lin, L., & Lv, J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016219 · Cited by 464
Sama, I. E., Ravera, A., Santema, B. T., van Goor, H., ter Maaten, J. M., Cleland, J. G. F., Rienstra, M., Friedrich, A. W., Samani, N. J., Ng, L. L., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa373 · Cited by 460
Danser, A. H. J., Epstein, M., & Batlle, D. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15082 · Cited by 457
The emerging role of ACE2 in physiology and disease
Hamming, I., Cooper, M., Haagmans, B., Hooper, N., Korstanje, R., Osterhaus, A., Timens, W., Turner, A., Navis, G., & van Goor, H. (2007) · The Journal of Pathology · doi:10.1002/path.2162 · Cited by 434
Kai, H., & Kai, M. (2020) · Hypertension Research · doi:10.1038/s41440-020-0455-8 · Cited by 426
Myocardial infarction increases ACE2 expression in rat and humans
Burrell, L. M., Risvanis, J., Kubota, E., Dean, R. G., MacDonald, P. S., Lu, S., Tikellis, C., Grant, S. L., Lew, R. A., Smith, A. I., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi114 · Cited by 423
Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis
Lippi, G., Wong, J., & Henry, B. M. (2020) · Polish Archives of Internal Medicine · doi:10.20452/pamw.15272 · Cited by 421
Cardiovascular manifestations and treatment considerations in COVID-19
Kang, Y., Chen, T., Mui, D., Ferrari, V., Jagasia, D., Scherrer-Crosbie, M., Chen, Y., & Han, Y. (2020) · Heart · doi:10.1136/heartjnl-2020-317056 · Cited by 411
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31030-8 · Cited by 408
Münzel, T., Hahad, O., Kuntic, M., Keaney, J. F., Deanfield, J. E., & Daiber, A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa460 · Cited by 406
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa433 · Cited by 403
Mehta, N., Kalra, A., Nowacki, A. S., Anjewierden, S., Han, Z., Bhat, P., Carmona-Rubio, A. E., Jacob, M., Procop, G. W., Harrington, S., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1855 · Cited by 400
SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?
Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395
Iaccarino, G., Grassi, G., Borghi, C., Ferri, C., Salvetti, M., Volpe, M., Cicero, A. F. G., Minuz, P., Muiesan, M. L., Mulatero, P., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15324 · Cited by 392
Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23618 · Cited by 387
Ferrario, C. M., Trask, A. J., & Jessup, J. A. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00618.2005 · Cited by 385
Self-citationPhysiological and pathological regulation of ACE2, the SARS-CoV-2 receptor
Li, Y., Zhou, W., Yang, L., & You, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104833 · Cited by 378
Fosbøl, E. L., Butt, J. H., Østergaard, L., Andersson, C., Selmer, C., Kragholm, K., Schou, M., Phelps, M., Gislason, G. H., Gerds, T. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.11301 · Cited by 377
Schiffrin, E. L., Flack, J. M., Ito, S., Muntner, P., & Webb, R. C. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa057 · Cited by 372
Kreutz, R., Algharably, E. A. E.-H., Azizi, M., Dobrowolski, P., Guzik, T., Januszewicz, A., Persu, A., Prejbisz, A., Riemer, T. G., Wang, J.-G., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa097 · Cited by 357
Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19
Bozkurt, B., Kovacs, R., & Harrington, B. (2020) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2020.04.013 · Cited by 355
Diaz, J. H. (2020) · Journal of Travel Medicine · doi:10.1093/jtm/taaa041 · Cited by 350
Muralidar, S., Ambi, S. V., Sekaran, S., & Krishnan, U. M. (2020) · Biochimie · doi:10.1016/j.biochi.2020.09.018 · Cited by 346
Aboudounya, M. M., & Heads, R. J. (2021) · Mediators of Inflammation · doi:10.1155/2021/8874339 · Cited by 346
ACE and ACE2 Activity in Diabetic Mice
Wysocki, J., Ye, M., Soler, M. J., Gurley, S. B., Xiao, H. D., Bernstein, K. E., Coffman, T. M., Chen, S., & Batlle, D. (2006) · Diabetes · doi:10.2337/db06-0033 · Cited by 339
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7)
Grobe, J. L., Mecca, A. P., Lingis, M., Shenoy, V., Bolton, T. A., Machado, J. M., Speth, R. C., Raizada, M. K., & Katovich, M. J. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00937.2006 · Cited by 332
Patel, V. B., Clarke, N., Wang, Z., Fan, D., Parajuli, N., Basu, R., Putko, B., Kassiri, Z., Turner, A. J., & Oudit, G. Y. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.11.017 · Cited by 321
Angiotensin‐converting enzyme 2 in the brain: properties and future directions
Xia, H., & Lazartigues, E. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05723.x · Cited by 321
Perico, L., Benigni, A., & Remuzzi, G. (2020) · Nephron · doi:10.1159/000507305 · Cited by 305
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler, M., & Esler, D. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002450 · Cited by 296
Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19
Li, G., He, X., Zhang, L., Ran, Q., Wang, J., Xiong, A., Wu, D., Chen, F., Sun, J., & Chang, C. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102463 · Cited by 290
COVID-19 and comorbidities: a systematic review and meta-analysis
Gold, M. S., Sehayek, D., Gabrielli, S., Zhang, X., McCusker, C., & Ben-Shoshan, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1786964 · Cited by 289
Current status of potential therapeutic candidates for the COVID-19 crisis
Zhang, J., Xie, B., & Hashimoto, K. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.046 · Cited by 283
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic
South, A. M., Tomlinson, L., Edmonston, D., Hiremath, S., & Sparks, M. A. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0279-4 · Cited by 282
Román, G. C., Spencer, P. S., Reis, J., Buguet, A., Faris, M. E. A., Katrak, S. M., Láinez, M., Medina, M. T., Meshram, C., Mizusawa, H., et al. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116884 · Cited by 280
ACE2 of the heart: From angiotensin I to angiotensin (1–7)
KEIDAR, S., KAPLAN, M., & GAMLIELLAZAROVICH, A. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.09.006 · Cited by 278
COVID-19 and Cancer: Current Challenges and Perspectives
Bakouny, Z., Hawley, J. E., Choueiri, T. K., Peters, S., Rini, B. I., Warner, J. L., & Painter, C. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.018 · Cited by 275
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
Trougakos, I. P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., Kastritis, E., Andreakos, E., & Dimopoulos, M. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.007 · Cited by 273
Ocaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273
Koka, V., Huang, X. R., Chung, A. C. K., Wang, W., Truong, L. D., & Lan, H. Y. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070762 · Cited by 271
Hernández Prada, J. A., Ferreira, A. J., Katovich, M. J., Shenoy, V., Qi, Y., Santos, R. A. S., Castellano, R. K., Lampkins, A. J., Gubala, V., Ostrov, D. A., et al. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.108944 · Cited by 271
COVID-19, Renin-Angiotensin System and Endothelial Dysfunction
Amraei, R., & Rahimi, N. (2020) · Cells · doi:10.3390/cells9071652 · Cited by 270
Rao, S., Lau, A., & So, H.-C. (2020) · Diabetes Care · doi:10.2337/dc20-0643 · Cited by 268
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19
Zipeto, D., Palmeira, J. D. F., Argañaraz, G. A., & Argañaraz, E. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.576745 · Cited by 267
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
Lee, I. T., Nakayama, T., Wu, C.-T., Goltsev, Y., Jiang, S., Gall, P. A., Liao, C.-K., Shih, L.-C., Schürch, C. M., McIlwain, D. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19145-6 · Cited by 263
Bader, F., Manla, Y., Atallah, B., & Starling, R. C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10008-2 · Cited by 259
Ferrario, C. M., Jessup, J., Gallagher, P. E., Averill, D. B., Brosnihan, K. B., Ann Tallant, E., Smith, R. D., & Chappell, M. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00675.x · Cited by 259
Self-citationDatta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 257
Sommerstein, R., Kochen, M. M., Messerli, F. H., & Gräni, C. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016509 · Cited by 254
Fernandes, T., Hashimoto, N. Y., Magalhães, F. C., Fernandes, F. B., Casarini, D. E., Carmona, A. K., Krieger, J. E., Phillips, M. I., & Oliveira, E. M. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168252 · Cited by 253
Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis
Li, X., Zhong, X., Wang, Y., Zeng, X., Luo, T., & Liu, Q. (2021) · PLOS ONE · doi:10.1371/journal.pone.0250602 · Cited by 236
COVID‐19 is an emergent disease of aging
Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., Kerepesi, C., Yim, S. H., Fedichev, P. O., & Gladyshev, V. N. (2020) · Aging Cell · doi:10.1111/acel.13230 · Cited by 172
COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system
Rysz, S., Al-Saadi, J., Sjöström, A., Farm, M., Campoccia Jalde, F., Plattén, M., Eriksson, H., Klein, M., Vargas-Paris, R., Nyrén, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22713-z · Cited by 111
Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications
Zahid, U., Ramachandran, P., Spitalewitz, S., Alasadi, L., Chakraborti, A., Azhar, M., Mikhalina, G., Sherazi, A., Narh, J. T., Khattar, P., et al. (2020) · American Journal of Nephrology · doi:10.1159/000511160 · Cited by 112
Sarzani, R., Giulietti, F., Di Pentima, C., Giordano, P., & Spannella, F. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00189.2020 · Cited by 86
Tuccori, M., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Focosi, D., & Blandizzi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00965-w · Cited by 80
Shah, H., Khan, M. S. H., Dhurandhar, N. V., & Hegde, V. (2021) · Acta Diabetologica · doi:10.1007/s00592-020-01636-z · Cited by 80
Cardiovascular disease and COVID ‐19: Australian and New Zealand consensus statement
Zaman, S., MacIsaac, A. I., Jennings, G. L., Schlaich, M. P., Inglis, S. C., Arnold, R., Kumar, S., Thomas, L., Wahi, S., Lo, S., et al. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50714 · Cited by 73
The depressor axis of the renin–angiotensin system and brain disorders: a translational approach
Gironacci, M. M., Vicario, A., Cerezo, G., & Silva, M. G. (2018) · Clinical Science · doi:10.1042/cs20180189 · Cited by 60
Matsuzawa, Y., Ogawa, H., Kimura, K., Konishi, M., Kirigaya, J., Fukui, K., Tsukahara, K., Shimizu, H., Iwabuchi, K., Yamada, Y., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00535-8 · Cited by 52
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25
COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J. L., & Gorriz, J. L. (2020) · Medicina de Familia. SEMERGEN · doi:10.1016/j.semerg.2020.05.005 · Cited by 21
Metadata
- Authors
- Ferrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E.
- Venue
- Circulation
- Published
- 2005-05-24
- Volume
- 111
- Issue
- 20
- Pages
- 2605-2610
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2028521865
- Cited by
- 1,565
- References
- 30
- FWCI
- 16.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.